MRKR — Marker Therapeutics Share News
0.000.00%
Last trade - 00:00- $16.01m
- $4.68m
- $3.55m
U.S. STOCKS ON THE MOVE-Atlassian, Chegg
U.S. STOCKS ON THE MOVE-DoorDash, Lyft, Carvana
Marker Therapeutics jumps after FDA clears cancer drug trial
Brief: Marker Therapeutics Announces FDA Clearance Of IND For MT-601 For Treatment Of Relapsed/Refractory Non-Hodgkin Lymphoma
Marker Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Marker Therapeutics Reports Q1 2022 Operating And Financial Results
U.S. STOCKS ON THE MOVE-Opthea Ltd, Carnival Corp, Tesla Inc
U.S. STOCKS ON THE MOVE-Polaris Inc, Invesco Ltd, Corning Inc
U.S. STOCKS ON THE MOVE-Hasbro, Cisco, DoorDash, Fastly, TripAdvisor
U.S. STOCKS ON THE MOVE-American Airlines, Travelers, Chinese tech ADRs
U.S. STOCKS ON THE MOVE-Microsoft, Didi, Applied UV
Marker Therapeutics slumps on stock offering
U.S. STOCKS ON THE MOVE-Intel Corp, Motorsport Games, Pacific Biosciences, Peloton Interactive
U.S. STOCKS ON THE MOVE-Zoom Video Communications, Inari Medical, Lordstown Motors, Rockwell Medical
U.S. STOCKS ON THE MOVE-Acorda Therapeutics, Exxon Mobil, Timber Pharma, Marker Therapeutics
U.S. STOCKS ON THE MOVE-Social media stocks, Golar LNG, Boeing, Marinus
Brief: Marker Therapeutics - Executed A Lease Agreement To Establish A Cgmp Manufacturing Facility In Houston
Brief: Marker Therapeutics Receives USAN Approval For "Zelenoleucel" As Nonproprietary Name For MT-401
Brief: Marker Therapeutics Reports Interim Results Of Its Multitaa-Specific T Cell Therapy In Patients With Pancreatic Adenocarcinoma